Tariffs on imported generic drugs could drive higher prices and reshape global supply chains, with a two-year zero-tariff window followed by 100% and 200% levies in later years. The plan could force manufacturers to reshore production and reallocate sourcing, potentially narrowing margins for generic drug makers, including Indian suppliers that supply a large share of U.S. prescriptions. Industry voices warn these tariffs may lead to reduced competition, higher patient costs, and possible exits from the U.S. market if margins are squeezed. Analysts expect reallocation of production and raw-material sourcing, potentially affecting APIs and overall drug availability, raising concerns about patient access and shortages if supply chains tighten. Some countries, such as Malaysia, see long-term risks for exporters with U.S. exposure, while the two-year window may serve as a negotiating tool to recalibrate investment and manufacturing. The overall narrative emphasizes the convergence of policy, pricing, and supply-chain strategies as healthcare systems and pharma players build resilience amid potential cost pressures and shortages.